| Antiproliferative activity against estrogen receptor positive human MCF7 cells after 72 hrs by MTT assay - BioAssay Summary New fluorinated 2-aryl-benzothiazoles, -benzoxazoles, and -chromen-4-ones have been synthesized and their activity against MCF-7 and MDA 468 breast cancer cell lines compared with the potent antitumor benzothiazole 5. Analogues such as 9a, b and 12a, d yielded submicromolar GI50 values in both cell lines; however, none of the new compounds approached 5 in terms of antitumor potency. For 5, binding to the aryl hydrocarbon receptor appeared to be necessary but not sufficient for growth inhibition. ..more |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioActive Compounds: 22 Description: Title: Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Abstract: New fluorinated 2-aryl-benzothiazoles, -benzoxazoles, and -chromen-4-ones have been synthesized and their activity against MCF-7 and MDA 468 breast cancer cell lines compared with the potent antitumor benzothiazole 5. Analogues such as 9a, b and 12a, d yielded submicromolar GI50 values in both cell lines; however, none of the new compounds approached 5 in terms of antitumor potency. For 5, binding to the aryl hydrocarbon receptor appeared to be necessary but not sufficient for growth inhibition. (PMID: 18666770) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Putative Target: ChEMBL Target ID: 80224 Target Type: CELL-LINE Cell Line: MCF7 Tissue: Breast carcinoma cells Pref Name: MCF7 Organism: Homo sapiens Tax ID: 9606 Confidence: Target assigned is non-molecular Relationship Type: Non-molecular target assigned Categorized Comment ChEMBL Assay Type: Functional ChEMBL Assay Data Source: Scientific Literature Result Definitions
* Activity Concentration. Data Table (Concise)
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||